One month after $115M megaround, muscle disease-focused Dyne goes public with $233M IPO
After completing a financing megaround for $115 million just a little over a month ago, Dyne Therapeutics is ready to hit the Nasdaq on Thursday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
